
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated a strong financial outlook following management's upward revisions, notably projecting global sales in the Neuroscience segment to reach approximately $10.7 billion by 2025, an increase from earlier forecasts. The company also raised its FY 2025 EPS guidance to a range of $12.09-$12.29 and adjusted revenue estimates upward by $700 million to around $59.7 billion, reflecting robust commercial performance driven by key products such as Skyrizi and Rinvoq. Additionally, AbbVie's first-quarter 2025 sales of $13.34 billion exceeded both internal and consensus expectations, indicating solid growth across its immunology and oncology franchises, despite some challenges in aesthetics and Humira sales.
Bears say
AbbVie faces significant risks that contribute to a negative outlook, including disappointing commercial performance across key products such as Skyrizi, Rinvoq, and Botox, which are critically reliant on market execution. The upcoming competition from biosimilars for Humira in 2025 is expected to lead to greater market share erosion, while limited growth in the neuroscience segment and challenges in the aesthetics portfolio are exacerbated by ongoing macroeconomic pressures. Additionally, pipeline delays, potential regulatory hurdles, and competitive dynamics in the oncology sector further complicate AbbVie's ability to meet long-term growth expectations, presenting further headwinds for the company's financial stability.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares